London: Thursday, June 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2017 on Monday, July 31, 2017 at 7:00 am British Summer Time (BST).
An analyst presentation will be held at 9:00 am BST (4:00 pm Hong Kong Time) on the same day at Panmure Gordon & Co, One New Change, London EC4M 9AF, UK, which will be webcast via the company website at www.chi-med.com/investors/event-information/. The presentation will be available to download before the analyst presentation begins.
For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Daylight Time (2:00 pm BST).
Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event.
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Christian Hogg, CEO
+852 2121 8200
Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
Brad Miles, BMC Communications
+1 (917) 570 7340 (Mobile)
Susan Duffy, BMC Communications
+1 (917) 499 8887 (Mobile)
Matt Beck, The Trout Group
+1 (917) 415 1750 (Mobile)
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
Richard Gray / Andrew Potts
+44 (20) 7886 2500